Long term outcomes to fludarabine and rituximab in
Introduction
Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder characterized primarily by bone marrow infiltration with lymphoplasmacytic cells, along with demonstration of an IgM monoclonal gammopathy [1] [2] [3] . Among treatment options for patients with WM, nucleoside analogues, as well as the CD20 directed monoclonal antibody rituximab have been commonly used. Response rates of 30-70% and durations of response of 20-24 months have been reported with the use of nucleoside analogues in WM patients [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Importantly, similar response rates were reported in these studies whether nucleoside analogues were employed as first line or salvage therapy. The use of rituximab has also been extensively evaluated in patients with WM. Using standard dose (i.e. 4 weekly infusions at 375 mg/m 2 ), overall response rates of 25-30% have been observed. More recently, an extended dose regimen giving rituximab at 375 mg/m 2 /week for 4 weeks, then repeated again at week 12 has resulted in higher (40-50%) overall response rates 4, [14] [15] [16] [17] [18] [19] .
In preclinical studies, the potential for rituximab and fludarabine to enhance each other's activity has been demonstrated, and may involve a spectrum of intracellular as well as extracellular mechanisms [20] [21] [22] . Moreover, in other indolent B-cell malignancies, the combination of rituximab and fludarabine has led to higher response rates than those observed with either agent alone [23] [24] [25] [26] [27] . The potential for enhanced clinical benefit by giving rituximab with fludarabine concurrently versus sequentially was has also been For personal use only. at Harvard Libraries on . www.bloodjournal.org From reported in patients with CLL 26 . In view of these considerations, we initiated a multicenter clinical trial of fludarabine and rituximab in patients with WM, which enrolled 43 subjects from March 7, 2001 to May 2, 2003 . The outcome and long term follow-up of this study are presented in this report.
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Patients and Methods
Patients with a clinicopathological diagnosis of WM requiring therapy who were naïve to fludarabine and rituximab, and who had 2 or less prior therapies, along with CD20 positive disease as determined by previous bone marrow immunohistochemistry or flow cytometry were eligible for this study. To meet eligibility patients had to demonstrate a monoclonal IgM protein, a minimum IgM level > 2 times the upper limit of normal, a baseline platelet count of > 25,000/uL, an absolute neutrophil count of > 500/uL, a serum creatinine of < 2.5 mg/dL (unless nephropathy was attributable to their WM), a serum total bilirubin and SGOT of < 2.5 times the upper limit of normal, and an ECOG performance status of 0-2. No chemotherapy, steroid therapy, or radiation therapy within 30 days of study entry was permitted. Patients who were pregnant or lactating, had serious co-morbid disease, had any uncontrolled bacterial, fungal or viral infection, or an active second malignancy were not eligible. All men and women of reproductive potential were required to agree to use an acceptable method of birth control before, during treatment, and for six months after completion of study treatment. Progressive disease was defined as occurring when a greater than 25% increase in serum IgM level occurred from the lowest attained response value or progression of clinically significant disease related symptom(s). Time to disease progression (TTP) was calculated from the start of therapy using the Kaplan Meier method. The primary endpoints of this study were determination of overall response, median progression free survival, and toxicity. A 48 month landmark analysis was also performed comparing patients with untreated versus previously treated disease and for those patients achieving > VGPR versus < VGPR.
Statistical analysis
Comparison of pre-and post-treatment parameters was performed using a two-tailed students t-test on Microsoft Excel™ software. Non-parametric testing of pre-and posttreatment variables was performed by Fisher's Exact t-test (Vassar Stats). A p-value < 0.05 was deemed to be significant for the above studies.
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Results

Patients and disease characteristics
Forty-three patients were enrolled in this study. The baseline characteristics for these patients are outlined in Table 1 . The median age for all enrolled patients was 61 (range 52-75) years old. The median number of treatments was 0 (range 0-2 prior therapies).
Twenty-seven (63%) patients had no prior therapy. Of the 16 previously treated patients, 14 and 2 patients were relapsed or refractory from their previous therapy, which included chlorambucil alone or with steroids (n=12), rituximab (n=2), vincristine, doxorubicin, dexamethasone (n=1), and autologous transplant (n=1). Median pre-therapy BM involvement with lymphoplasmacytic cells was 55% (range 5-100%), and median serum IgM level was 3,840 mg/dL (range 655 mg/dL to 10,500 mg/dL). Twenty-seven (63%) patients had an IgM level of >3,000 mg/dL. The median pre-therapy hematocrit and platelet count for all enrolled study patients was 31.2% (range 23.2-44.7%), and 252,000 (range 55,000-597,000/mm 3 ), respectively. Fifteen (35%) and 4 (9.3%) of the patients had a hematocrit <30% and a platelet count of <100,000/mm 3 , respectively. Five patients (12%) had adenopathy and/or splenomegaly.
Of the 43 patients enrolled on study, 41 were eligible for and received therapy beyond week 12. One patient was removed from study at week 4 after experiencing an intracerebral bleed resulting from hyperviscosity induced by rituximab, while another 
Response
The individual changes in serum IgM levels at best response for all patients are shown in 
Time to progression
The median time to progression for all patients was 51.2 months (Figure 2 
Changes in hematological parameters in treated WM patients.
A significant increase in the median hematocrit was noted for all patients from 31.2% (range 23.2-44.7%) before therapy to 38.0% (range 24.9-45.9%) following treatment (p<0.0008), with 30 of the 43 (70%) patients demonstrating a hematocrit rise of >2%.
Conversely, the median platelet count decreased following treatment from 252,000/mm 3 (range 55,000-597,000/mm 3 though for most patients this decrease was not clinically significant. Pre-therapy, 15 (35%) and 4 (9.3%) of the 43 patients demonstrated a hematocrit <30% and a platelet count of <100,000/mm 3 , respectively. Following therapy, 6 (13.9%) and 6 (13.9%) of the 43 patients demonstrated a hematocrit of <30%, and platelet count of <100,000/mm 3 (p=0.043 and 0.74, respectively).
Adverse Events
Toxicities encountered were mainly hematological and infectious. Encountered toxicities An interesting observation in this study was that for responding patients achieving at least a very good partial response (i.e. at least a 90% reduction in disease burden), TTP was significantly greater versus patients attaining less than a VGPR (77.6 versus 38.4 months, respectively). While the importance of attaining a VGPR has been reported as a predictive variable for progression free survival in multiple myeloma 31, 32 , this study to
knowledge, constitutes the first report of such potential benefit in WM. Studies addressing the impact of achieving at least a VGPR with other therapies would therefore seem appropriate in order to clarify whether VGPR attainment is categorical or therapy specific in terms of TTP benefit.
An intriguing finding in this study was the late response activity, as evidenced by the median time to best response which was 19.2 (range 4.2-61) months. Continued declines in serum IgM beyond one year have previously been reported by our group and Dimopoulos et al among patients receiving rituximab monotherapy 18, 19 . One possibility for this finding is that fludarabine and rituximab may more effectively target earlier members of the WM clone i.e. mature B-cells and lymphoplasmacytic cells, and spare (at least initially) more differentiated plasma cell members. Indeed, the relative resistance of malignant plasma cells to rituximab and/or fludarabine has previously been reported by us and others 33, 34 , and may account for the frequent detection of residual plasma cells in the absence of earlier B-cell precursors in the bone marrows of patients treated with either agent alone or in combination. The eventual clonal extinction of IgM producing plasma cells might then follow the initial elimination of precursor B-cells by fludarabine and rituximab thereby accounting for the slow, but continued declines in serum IgM observed in these studies.
An important consideration in this study was the differential impact of combined fludarabine and rituximab therapy on hematological parameters. A significant increase in the median hematocrit was noted for all patients from 31.2% to 38.0% following treatment, with 30 of the 43 (70%) patients demonstrating a hematocrit rise of >2%.
While the impact on hematocrit proved to be a positive outcome for patients, some patients experienced significant neutropenia and thrombocytopenia, which led to treatment discontinuation in 9 (21%) patients. Among these patients, 3 subjects experienced grade 4 neutropenia lasting more than 6 months. In two of these subjects, we observed a prompt recovery in neutrophil count following switch in cytokine support from granulocyte colony stimulating factor (G-CSF) to granulocyte-monocyte colony stimulating factor (GM-CSF), suggesting that the stimulation of earlier lineage leukocytes may overcome nucleoside analogue related prolonged neutropenia in certain patients.
In addition to hematological toxicities, infectious complications were encountered in this study and may have contributed to the death of two patients who succumbed to non-PCP related interstitial pneumonia, including one patient who was in a complete remission at time of death. Similar complications to nucleoside analogue therapy have previously been described 35 . In addition, we observed herpes zoster in 3 of the first 21 patients prompting institution of herpes zoster prophylaxis with acyclovir or famcyclovir for the duration of treatment plus one year with good effect. The increased incidence of herpes zoster has also been reported by Czuczman et al 23 in patients with follicular NHL treated with fludarabine and rituximab, prompting prophylaxis in their study as well. Therefore, prophylaxis with an anti-viral agent appears warranted among WM patients receiving fludarabine and rituximab. Lastly, in one patient, we observed a case of limbic encephalitis, whose pathogenic basis remains unknown despite extensive workup but suspected to be on the basis of a herpetic infection. Viral encephalitis suspected on the basis of a herpetic infection was previously reported in a WM patient receiving treatment with cladribine 8 .
In addition to the above short term toxicities, we also observed the development of diffuse large cell lymphoma (n=3), myelodysplasia and acute myelogenous leukemia (n=3), and carcinomas (n=2) among patients treated in this study with a median followup period of 40.3 months. While previous alkylator therapy may have been contributory in some of these cases to the development of secondary malignancies, only half of these patients received such therapy. The increased incidence of transformation to aggressive lymphoma and/or development of myelodysplasia and acute myelogenous leukemia following nucleoside analogue therapy have previously been reported by us 36 and others 37 , and raises concerns about the long term consequences of these agents.
Therefore, careful consideration of the candidacy for individual WM patients must be undertaken in order to discern if nucleoside analogue therapy is appropriate, as has also been recommended by the recent consensus panels on treatment of WM 4, 38 . The results of this study may also call into question whether a full 6 cycle course of fludarabine utilizing 5 days of therapy per cycle is warranted, particularly since 20% of patients experienced cytopenias resulting in treatment cessation. In most of these cases, treatment was truncated at or after 4 cycles of fludarabine. The impact of utilizing abbreviated courses of nucleoside analogues is therefore worthy of further study, as is also its potential impact on mitigating secondary malignancies.
Lastly, the sequencing of rituximab to fludarabine may be an important factor both from an efficacy standpoint, as well as avoidance of the IgM flare that commonly is observed following rituximab 28, 29 and which may have life threatening consequences as was the case in one patient in this study who experienced a hyperviscosity related intracerebral bleed following the first 4 weekly infusions of rituximab. Byrd et al 26 reported that the concurrent sequencing of fludarabine and rituximab produced a higher overall and complete remission response rate versus fludarabine followed by rituximab in CLL patients. The concurrent administration of these agents versus rituximab first followed by fludarabine as administered in this study might therefore lead to a better outcome in the treatment of WM patients. Moreover, as reported by Nichols et al 40 and Tedeshi et al 39 , the concurrent administration of fludarabine and rituximab may also be associated with a decreased frequency of IgM flaring.
In conclusion, the results of this study demonstrate that fludarabine and rituximab is an active regimen in WM, though the ideal schedule and length of treatment for this combination needs to be better studied, and short and long term toxicities need to be carefully weighed against other available treatment options. The sequencing, combination, and duration of therapy to best optimize the combination of purine nucleoside analogues and rituximab remains to be defined by larger randomized studies. 
